Symbols / PTGX
PTGX Chart
About
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 5.46B |
| Enterprise Value | 4.90B | Income | 45.91M | Sales | 209.22M |
| Book/sh | 10.34 | Cash/sh | 9.22 | Dividend Yield | — |
| Payout | 0.00% | Employees | 128 | IPO | — |
| P/E | 132.41 | Forward P/E | 55.69 | PEG | — |
| P/S | 26.11 | P/B | 8.45 | P/C | — |
| EV/EBITDA | 244.53 | EV/Sales | 23.41 | Quick Ratio | 12.94 |
| Current Ratio | 13.05 | Debt/Eq | 1.67 | LT Debt/Eq | — |
| EPS (ttm) | 0.66 | EPS next Y | 1.57 | EPS Growth | — |
| Revenue Growth | 0.80% | Earnings | 2026-02-27 | ROA | 1.82% |
| ROE | 7.80% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -9.85% | Profit Margin | 21.94% | Shs Outstand | 62.52M |
| Shs Float | 50.61M | Short Float | 15.58% | Short Ratio | 9.74 |
| Short Interest | — | 52W High | 96.54 | 52W Low | 33.70 |
| Beta | 2.25 | Avg Volume | 826.61K | Volume | 659.85K |
| Target Price | $101.92 | Recom | Strong_buy | Prev Close | $86.59 |
| Price | $87.39 | Change | 0.92% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$101.92
Mean price target
2. Current target
$87.39
Latest analyst target
3. DCF / Fair value
$15.29
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$87.39
Low
$65.00
High
$118.00
Mean
$101.92
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-02 | main | Jefferies | Buy → Buy | $118 |
| 2026-01-30 | main | HC Wainwright & Co. | Buy → Buy | $117 |
| 2026-01-05 | main | Truist Securities | Buy → Buy | $110 |
| 2025-12-17 | main | Barclays | Overweight → Overweight | $108 |
| 2025-12-08 | main | Citigroup | Buy → Buy | $115 |
| 2025-11-10 | main | Citigroup | Buy → Buy | $98 |
| 2025-11-07 | main | JP Morgan | Overweight → Overweight | $81 |
| 2025-11-07 | main | Barclays | Overweight → Overweight | $88 |
| 2025-11-07 | main | Citizens | Market Outperform → Market Outperform | $102 |
| 2025-10-28 | main | Truist Securities | Buy → Buy | $88 |
| 2025-10-28 | main | Wedbush | Outperform → Outperform | $86 |
| 2025-10-28 | reit | BTIG | Buy → Buy | $82 |
| 2025-10-17 | main | Citigroup | Buy → Buy | $96 |
| 2025-10-08 | reit | HC Wainwright & Co. | Buy → Buy | $80 |
| 2025-09-17 | reit | HC Wainwright & Co. | Buy → Buy | $80 |
| 2025-09-17 | init | Barclays | — → Overweight | $72 |
| 2025-09-12 | init | Leerink Partners | — → Outperform | $73 |
| 2025-08-07 | main | JMP Securities | Market Outperform → Market Outperform | $69 |
| 2025-06-17 | init | Citigroup | — → Buy | $72 |
| 2025-06-03 | reit | HC Wainwright & Co. | Buy → Buy | $80 |
- Protagonist CEO lines up five healthcare investor events for March - Stock Titan ue, 24 Feb 2026 12
- Insider Sale: Director at $PTGX Sells 18,000 Shares - Quiver Quantitative Wed, 18 Feb 2026 23
- Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Evaluating a 25% Upside Potential in the Biotech Sector - DirectorsTalk Interviews ue, 17 Feb 2026 14
- Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal - Yahoo Finance Mon, 13 Oct 2025 07
- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat hu, 19 Feb 2026 06
- Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes - The Motley Fool Sun, 01 Feb 2026 08
- Protagonist Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis Sun, 21 Dec 2025 08
- RTW INVESTMENTS, LP Reduces Stake in Protagonist Therapeutics Inc - GuruFocus Sat, 21 Feb 2026 08
- Ali Asif, CFO of protagonist, sells $3.8m in PTGX stock - Investing.com ue, 27 Jan 2026 08
- Protagonist Therapeutics: Assessing The 2026 Upside For Icotrokinra And Rusfertide - Seeking Alpha Fri, 30 Jan 2026 08
- Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) 51% Price Boost Is Out Of Tune With Revenues - simplywall.st Sat, 11 Oct 2025 07
- Protagonist Therapeutics (NASDAQ:PTGX) Director Lewis Williams Sells 18,000 Shares - MarketBeat hu, 19 Feb 2026 00
- Protagonist Therapeutics (PTGX): Evaluating Valuation After a 65% Year-to-Date Share Price Surge - Yahoo Finance ue, 07 Oct 2025 07
- Protagonist (PTGX) Stock Pre-Market (-6.4%): NDA Submission For Rusfertide Triggers Sell-The-News - Trefis ue, 06 Jan 2026 08
- $PTGX stock is up 31% today. Here's what we see in our data. - Quiver Quantitative Fri, 10 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 18000 | 1483560 | — | Sale at price 82.42 per share. | WILLIAMS LEWIS T | Director | — | 2026-02-17 00:00:00 | D |
| 1 | 18000 | 195120 | — | Conversion of Exercise of derivative security at price 10.84 per share. | WILLIAMS LEWIS T | Director | — | 2026-02-17 00:00:00 | D |
| 2 | 20000 | 1673600 | — | Sale at price 83.68 per share. | WADDILL WILLIAM D | Director | — | 2026-02-06 00:00:00 | D |
| 3 | 20000 | 166200 | — | Conversion of Exercise of derivative security at price 8.31 per share. | WADDILL WILLIAM D | Director | — | 2026-02-06 00:00:00 | D |
| 4 | 23151 | 1905305 | — | Sale at price 82.00 - 82.42 per share. | MOLINA ARTURO MD | Officer | — | 2026-01-27 00:00:00 | D |
| 5 | 10000 | 80400 | — | Conversion of Exercise of derivative security at price 8.04 per share. | MOLINA ARTURO MD | Officer | — | 2026-01-27 00:00:00 | D |
| 6 | 46203 | 3841037 | — | Sale at price 83.13 - 83.14 per share. | ALI ASIF | Chief Financial Officer | — | 2026-01-27 00:00:00 | D |
| 7 | 28000 | 453080 | — | Conversion of Exercise of derivative security at price 12.17 - 19.19 per share. | ALI ASIF | Chief Financial Officer | — | 2026-01-27 00:00:00 | D |
| 8 | 48273 | 4063743 | — | Sale at price 83.19 - 84.59 per share. | PATEL DINESH V | Chief Executive Officer | — | 2026-01-27 00:00:00 | D |
| 9 | 48273 | 520631 | — | Conversion of Exercise of derivative security at price 4.21 - 21.58 per share. | PATEL DINESH V | Chief Executive Officer | — | 2026-01-27 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.01 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | 255.74M | -90.34M | -128.00M | -123.07M |
| TotalUnusualItems | 0.00 | 0.00 | ||
| TotalUnusualItemsExcludingGoodwill | 0.00 | 0.00 | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | 275.19M | -78.95M | -127.39M | -125.55M |
| ReconciledDepreciation | 2.90M | 3.31M | 3.37M | 2.77M |
| EBITDA | 255.74M | -90.34M | -128.00M | -123.07M |
| EBIT | 252.84M | -93.65M | -131.37M | -125.84M |
| NetInterestIncome | 26.32M | 14.90M | 4.06M | 443.00K |
| InterestExpense | 0.00 | 0.00 | ||
| InterestIncome | 26.32M | 14.90M | 4.06M | 443.00K |
| NormalizedIncome | 275.19M | -78.95M | -127.39M | -125.55M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 275.19M | -78.95M | -127.39M | -125.55M |
| TotalExpenses | 181.59M | 153.65M | 157.95M | 153.20M |
| TotalOperatingIncomeAsReported | 252.84M | -93.65M | -131.37M | -125.84M |
| DilutedAverageShares | 65.08M | 56.76M | 49.04M | 46.32M |
| BasicAverageShares | 61.57M | 56.76M | 49.04M | 46.32M |
| DilutedEPS | 4.23 | -1.39 | -2.60 | -2.71 |
| BasicEPS | 4.47 | -1.39 | -2.60 | -2.71 |
| DilutedNIAvailtoComStockholders | 275.19M | -78.95M | -127.39M | -125.55M |
| NetIncomeCommonStockholders | 275.19M | -78.95M | -127.39M | -125.55M |
| NetIncome | 275.19M | -78.95M | -127.39M | -125.55M |
| NetIncomeIncludingNoncontrollingInterests | 275.19M | -78.95M | -127.39M | -125.55M |
| NetIncomeContinuousOperations | 275.19M | -78.95M | -127.39M | -125.55M |
| TaxProvision | 4.22M | 0.00 | 0.00 | 0.00 |
| PretaxIncome | 279.41M | -78.95M | -127.39M | -125.55M |
| OtherIncomeExpense | 250.00K | -201.00K | -80.00K | -149.00K |
| OtherNonOperatingIncomeExpenses | 250.00K | -201.00K | -80.00K | -149.00K |
| SpecialIncomeCharges | 0.00 | 0.00 | ||
| NetNonOperatingInterestIncomeExpense | 26.32M | 14.90M | 4.06M | 443.00K |
| InterestExpenseNonOperating | 0.00 | 0.00 | ||
| InterestIncomeNonOperating | 26.32M | 14.90M | 4.06M | 443.00K |
| OperatingIncome | 252.84M | -93.65M | -131.37M | -125.84M |
| OperatingExpense | 181.59M | 153.65M | 157.95M | 153.20M |
| ResearchAndDevelopment | 138.13M | 120.16M | 126.22M | 126.01M |
| SellingGeneralAndAdministration | 43.46M | 33.49M | 31.74M | 27.20M |
| GeneralAndAdministrativeExpense | 43.46M | 33.49M | 31.74M | 27.20M |
| OtherGandA | 43.46M | 33.49M | 31.74M | 27.20M |
| TotalRevenue | 434.43M | 60.00M | 26.58M | 27.36M |
| OperatingRevenue | 434.43M | 60.00M | 26.58M | 27.36M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 61.04M | 57.71M | 49.34M | 47.84M |
| ShareIssued | 61.04M | 57.71M | 49.34M | 47.84M |
| TotalDebt | 10.87M | 1.14M | 3.66M | 5.86M |
| TangibleBookValue | 675.29M | 336.68M | 215.61M | 300.02M |
| InvestedCapital | 675.29M | 336.68M | 215.61M | 300.02M |
| WorkingCapital | 544.24M | 334.30M | 211.90M | 296.72M |
| NetTangibleAssets | 675.29M | 336.68M | 215.61M | 300.02M |
| CapitalLeaseObligations | 10.87M | 1.14M | 3.66M | 5.86M |
| CommonStockEquity | 675.29M | 336.68M | 215.61M | 300.02M |
| TotalCapitalization | 675.29M | 336.68M | 215.61M | 300.02M |
| TotalEquityGrossMinorityInterest | 675.29M | 336.68M | 215.61M | 300.02M |
| StockholdersEquity | 675.29M | 336.68M | 215.61M | 300.02M |
| GainsLossesNotAffectingRetainedEarnings | -82.00K | -105.00K | -359.00K | -299.00K |
| OtherEquityAdjustments | -82.00K | -105.00K | -359.00K | -299.00K |
| RetainedEarnings | -340.52M | -615.71M | -536.75M | -409.36M |
| AdditionalPaidInCapital | 1.02B | 952.49M | 752.72M | 709.68M |
| CapitalStock | 1.00K | 1.00K | 0.00 | 0.00 |
| CommonStock | 1.00K | 1.00K | 0.00 | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 69.43M | 21.27M | 32.32M | 47.67M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 22.03M | 0.00 | 1.14M | 3.66M |
| NonCurrentDeferredLiabilities | 11.68M | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 10.36M | 0.00 | 1.14M | 3.66M |
| LongTermCapitalLeaseObligation | 10.36M | 0.00 | 1.14M | 3.66M |
| CurrentLiabilities | 47.40M | 21.27M | 31.18M | 44.02M |
| CurrentDeferredLiabilities | 18.89M | 3.00K | 69.00K | 2.50M |
| CurrentDeferredRevenue | 18.89M | 3.00K | 69.00K | 2.50M |
| CurrentDebtAndCapitalLeaseObligation | 510.00K | 1.14M | 2.52M | 2.20M |
| CurrentCapitalLeaseObligation | 510.00K | 1.14M | 2.52M | 2.20M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 11.08M | 6.79M | 4.97M | 7.12M |
| PayablesAndAccruedExpenses | 16.92M | 13.34M | 23.63M | 32.19M |
| CurrentAccruedExpenses | 12.54M | 12.47M | 19.57M | 30.18M |
| Payables | 4.38M | 871.00K | 4.05M | 2.01M |
| OtherPayable | 74.00K | 99.00K | 415.00K | 407.00K |
| DuetoRelatedPartiesCurrent | 69.00K | 899.00K | ||
| TotalTaxPayable | 2.69M | 0.00 | ||
| IncomeTaxPayable | 2.69M | 0.00 | ||
| AccountsPayable | 1.61M | 772.00K | 3.64M | 1.60M |
| TotalAssets | 744.73M | 357.95M | 247.93M | 347.69M |
| TotalNonCurrentAssets | 153.08M | 2.37M | 4.85M | 6.96M |
| OtherNonCurrentAssets | 225.00K | 225.00K | 225.00K | 225.00K |
| InvestmentsAndAdvances | 140.25M | 0.00 | 0.00 | |
| InvestmentinFinancialAssets | 0.00 | |||
| NetPPE | 12.61M | 2.15M | 4.63M | 6.73M |
| AccumulatedDepreciation | -7.04M | -6.23M | -5.25M | -4.26M |
| GrossPPE | 19.64M | 8.38M | 9.88M | 10.99M |
| Leases | 2.42M | 963.00K | 913.00K | 877.00K |
| OtherProperties | 15.77M | 6.28M | 7.88M | 9.09M |
| MachineryFurnitureEquipment | 1.45M | 1.14M | 1.09M | 1.02M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 591.64M | 355.58M | 243.08M | 340.74M |
| OtherCurrentAssets | 42.00K | 975.00K | ||
| RestrictedCash | 0.00 | |||
| PrepaidAssets | 4.24M | 3.63M | 5.67M | 8.50M |
| Receivables | 168.49M | 10.33M | 52.00K | 5.33M |
| OtherReceivables | 248.00K | 76.00K | 42.00K | 975.00K |
| DuefromRelatedPartiesCurrent | 165.00M | 10.00M | 10.00K | 1.57M |
| TaxesReceivable | 0.00 | 2.79M | ||
| AccruedInterestReceivable | 3.24M | 256.00K | ||
| CashCashEquivalentsAndShortTermInvestments | 418.91M | 341.62M | 237.35M | 326.90M |
| OtherShortTermInvestments | 321.66M | 154.89M | 111.61M | 203.24M |
| CashAndCashEquivalents | 97.25M | 186.73M | 125.74M | 123.67M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 182.80M | -70.84M | -108.93M | -108.97M |
| RepaymentOfDebt | 0.00 | 0.00 | ||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 0.00 | 132.10M | 14.55M | 123.83M |
| CapitalExpenditure | -1.35M | -609.00K | -795.00K | -1.10M |
| InterestPaidSupplementalData | 1.53M | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 97.47M | 186.95M | 125.97M | 123.89M |
| BeginningCashPosition | 186.95M | 125.97M | 123.89M | 117.82M |
| EffectOfExchangeRateChanges | 0.00 | 0.00 | -90.00K | -126.00K |
| ChangesInCash | -89.48M | 60.98M | 2.17M | 6.20M |
| FinancingCashFlow | 25.85M | 170.48M | 18.84M | 129.92M |
| CashFlowFromContinuingFinancingActivities | 25.85M | 170.48M | 18.84M | 129.92M |
| NetOtherFinancingCharges | -600.00K | -769.00K | -163.00K | -189.00K |
| ProceedsFromStockOptionExercised | 26.45M | 39.15M | 4.45M | 6.28M |
| NetCommonStockIssuance | 0.00 | 132.10M | 14.55M | 123.83M |
| CommonStockIssuance | 0.00 | 132.10M | 14.55M | 123.83M |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | ||
| NetLongTermDebtIssuance | 0.00 | 0.00 | ||
| LongTermDebtPayments | 0.00 | 0.00 | ||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -299.48M | -39.26M | 91.47M | -15.86M |
| CashFlowFromContinuingInvestingActivities | -299.48M | -39.26M | 91.47M | -15.86M |
| NetInvestmentPurchaseAndSale | -298.13M | -38.65M | 92.26M | -14.76M |
| SaleOfInvestment | 323.57M | 152.40M | 307.14M | 271.83M |
| PurchaseOfInvestment | -621.70M | -191.04M | -214.87M | -286.59M |
| NetPPEPurchaseAndSale | -1.35M | -609.00K | -795.00K | -1.10M |
| PurchaseOfPPE | -1.35M | -609.00K | -795.00K | -1.10M |
| OperatingCashFlow | 184.15M | -70.24M | -108.14M | -107.86M |
| CashFlowFromContinuingOperatingActivities | 184.15M | -70.24M | -108.14M | -107.86M |
| ChangeInWorkingCapital | -122.61M | -19.51M | -7.77M | -3.31M |
| ChangeInOtherWorkingCapital | 30.57M | -1.60M | -12.88M | |
| ChangeInOtherCurrentLiabilities | -2.23M | -2.74M | -2.66M | -2.17M |
| ChangeInPayablesAndAccruedExpense | 7.82M | -8.53M | -11.50M | 15.87M |
| ChangeInAccruedExpense | 4.29M | -5.60M | -12.71M | 19.10M |
| ChangeInPayable | 3.53M | -2.93M | 1.22M | -3.22M |
| ChangeInAccountPayable | 842.00K | -2.87M | 2.04M | -1.39M |
| ChangeInTaxPayable | 2.69M | 0.00 | 0.00 | |
| ChangeInIncomeTaxPayable | 2.69M | 0.00 | 0.00 | |
| ChangeInPrepaidAssets | -3.77M | 1.75M | 3.75M | -3.23M |
| ChangeInReceivables | -155.00M | -9.99M | 4.24M | -915.00K |
| OtherNonCashItems | 194.00K | |||
| StockBasedCompensation | 37.55M | 29.29M | 24.20M | 16.39M |
| AmortizationOfSecurities | -8.88M | -4.57M | -549.00K | 1.83M |
| DeferredTax | 0.00 | 0.00 | ||
| DeferredIncomeTax | 0.00 | 0.00 | ||
| DepreciationAmortizationDepletion | 2.90M | 3.31M | 3.37M | 2.77M |
| DepreciationAndAmortization | 2.90M | 3.31M | 3.37M | 2.77M |
| Depreciation | 2.90M | 3.31M | 3.37M | 2.77M |
| GainLossOnSaleOfPPE | 0.00 | |||
| NetIncomeFromContinuingOperations | 275.19M | -78.95M | -127.39M | -125.55M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PTGX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|